Oramed Reports Fiscal Third Quarter 2025 Financial Results

Rhea-AI Summary

Oramed (Nasdaq: ORMP) reported unaudited results for the nine months ended Sept 30, 2025, posting a pre-tax net income of $65.0 million versus a $6.1 million loss a year earlier.

Key drivers include the completed $100 million cash repayment from Scilex (about $27 million received in the period) and substantial unrealized fair-value gains from the company's equity holdings including Alpha Tau Medical. Total assets rose 42% year-over-year to $220.5 million. Basic EPS was $1.30 and diluted EPS $1.26. R&D expense declined to $4.4 million while G&A rose to $5.0 million for the nine-months.

Positive

• Net income (pre-tax) of $65.0 million for nine months
• Completed Scilex repayment totaling $100 million principal returned
• Total assets increased 42% to $220.5 million YoY
• Basic EPS of $1.30 for the nine-month period
• R&D expenses decreased from $4.9M to $4.4M

Negative

• G&A expenses increased from $4.3M to $5.0M (≈16% rise)

Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million

NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025.

Nine-Month Period 2025 Financial Highlights:

• Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last year
• Completed full repayment from Scilex: Received approximately $27 million during the period, bringing total repayment to $100 million and representing full return of principal from the Company's strategic investment
• Strong per-share performance: Basic earnings per share of $1.30; diluted earnings per share of $1.26
• Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year
• Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million

The significant improvement in net income was primarily driven by the combination of realized cash returns from Scilex Holding Company and substantial unrealized fair-value gains from the Company's equity holdings in Alpha Tau Medical Ltd. and other investments.

Management Commentary

Nadav Kidron, Chief Executive Officer of Oramed, commented: "Our disciplined investment strategy is delivering strong results. The complete $100 million cash repayment from Scilex, combined with substantial unrealized gains from our Alpha Tau position an other investments, has driven our $65 million net income and positioned us with greater financial flexibility to pursue strategic opportunities while advancing our oral drug delivery platform."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption.
For more information, please visit www.oramed.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our trial plans, expected returns from our investment portfolio, our growth initiatives, potential partnerships, dividend plans, and our ability to create shareholder value through our diversified approach. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and our ability to identify and execute partnerships. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions or updates to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Company Contact:
+1-844-9-ORAMED
ir@oramed.com

Logo: https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/oramed-reports-fiscal-third-quarter-2025-financial-results-302617174.html

SOURCE Oramed Pharmaceuticals Inc.

FAQ

What drove Oramed's net income of $65.0M for the nine months ended Sept 30, 2025 (ORMP)?

Oramed cited the $100M cash repayment from Scilex plus substantial unrealized fair-value gains from equity holdings including Alpha Tau as primary drivers.

How much did Oramed's total assets change in the nine months to Sept 30, 2025 (ORMP)?

Total assets rose 42% year-over-year to $220.5 million.

What were Oramed's reported EPS figures for the nine months ended Sept 30, 2025 (ORMP)?

Oramed reported basic EPS $1.30 and diluted EPS $1.26 for the period.

Did Oramed receive the full repayment from Scilex and how much was received during the period (ORMP)?

Yes; the company completed full repayment with approximately $27 million received during the period, bringing total repayment to $100 million.

How did Oramed's operating expenses change in the nine months to Sept 30, 2025 (ORMP)?

R&D decreased to $4.4M from $4.9M, while G&A increased to $5.0M from $4.3M.

What impact did Oramed say the investment portfolio had on its 2025 nine-month results (ORMP)?

Management attributed the improved results to disciplined investing: the Scilex repayment plus substantial unrealized gains from equity positions increased net income and financial flexibility.